Previous 10 | Next 10 |
Total revenue of $16.2 million and diluted earnings per share (EPS) of $0.20 Maintains full-year revenue guidance of $59.3 - $62.0 million (+10-15%) and EPS guidance of $0.63 - $0.67 Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and...
2023-07-05 17:35:21 ET LEVI , SLP For Seeking Alpha's full earnings season calendar, click here . For further details see: Notable earnings after Thursday's close
2023-07-02 07:18:39 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . For further details see: Wall Street Breakfast: The Week Ahead
2023-06-30 15:00:00 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...
Conference call to be on Thursday, July 6, 2023, at 5 p.m. EDT Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report third quarter fiscal 2023 financial results after the market close on Thursday, July 6, 2023. Management will...
Acquisition increases breadth and depth of QSP expertise and range of therapeutic applications Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today ann...
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of a new integrated pulmonary software and services package. This targeted package will support pharmaceutical companies ...
2023-05-02 12:38:45 ET Summary Simulations Plus, Inc. is a company that develops software for drug discovery and development using artificial intelligence and machine learning technology. SLP has seen what was very impressive growth begin to quickly slow. Retention data sugges...
Provides FDA with software tools to investigate drug-induced liver injury in clinical trials Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that the U.S. FDA has rene...
2023-04-05 20:09:08 ET Simulations Plus, Inc. (SLP) Q2 2023 Earnings Conference Call March 05, 2023 05:00 PM ET Company Participants Brian Siegel - Hayden IR Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer Conference Call P...
News, Short Squeeze, Breakout and More Instantly...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance an...
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulati...
2024-06-24 16:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...